ArticleJournal of asthma and allergy2025
Exploring Nrf2 as a Potential Biomarker in Asthma: Links to Hypoxia, Oxidative Stress, and Ferroptosis in a Cross-Sectional Study.
Article in Journal of asthma and allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis in diabetic retinopathy: from pathogenic mechanisms to translational prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to explore the potential role of Nrf2 as a biomarker in asthma and its associations with hypoxia, oxidative stress, and ferroptosis-related indicators in a cross-sectional study. Patients and Methods: This study involved the collection of peripheral blood samples from participants to isolate serum and peripheral blood mononuclear cells (PBMCs). Enzyme-linked immunosorbent assay (ELISA) and other assay kits was performed to quantify the levels of Nrf2, HIF-1α, SOD, and MDA in PBMCs, alongside the activities of SOD and GSH-Px, and serum concentrations of IL-4 and IL-13. Quantitative Real-time PCR (qRT-PCR) was used to assess the expression levels of GPX4, NCOA4, SCL7A11, and HMGB1 in PBMCs. Clinical data were collected and analyzed statistically. Receiver operating characteristic (ROC) curve analysis was employed to assess the diagnostic performance of these indicators. Results: Compared with the control group, asthma patients showed significantly lower levels of Nrf2 and SOD in PBMCs, as well as reduced expression of GPX4, SCL7A11, and NCOA4 (P < 0.05). In contrast, levels of HIF-1α and MDA, as well as the expression of HMGB1, were significantly elevated in the asthma group (P < 0.05). Correlation analysis indicated that Nrf2, HIF-1α, and MDA levels in PBMCs were associated with certain clinical indicators in asthma patients. ROC curve analysis further demonstrated that these indicators exhibited a certain diagnostic performance for asthma and severe asthma. Additionally, in asthma patients, Nrf2 expression in PBMCs was negatively correlated with HIF-1α levels and eosinophil counts, but positively correlated with SOD and GPX4 levels. Conclusion: The interplay between hypoxia, oxidative stress, and ferroptosis may be involved in asthma pathogenesis. Based on the findings, Nrf2 may have potential as a biomarker for asthma. However, given the study's limitations, further research is needed to confirm these associations and fully understand the role of Nrf2 in asthma diagnosis and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.